Single B Cell Screening Platform

Single B cell screening technologies enable rapid isolation and characterization of antigen-specific antibody-producing B cells at the single-cell level. Compared with conventional hybridoma workflows, single B cell approaches can significantly shorten antibody discovery timelines while preserving the natural heavy- and light-chain pairing of antibodies derived from immunized hosts or convalescent samples.

At Biocrest Science, we provide integrated single B cell screening services for researchers seeking rapid monoclonal antibody discovery, recombinant antibody generation, and lead candidate identification. Our platform combines advanced cell sorting, microfluidics-based screening, antibody sequencing, and recombinant expression workflows to support applications ranging from research-use antibodies to early therapeutic development.

Species We Serve

Single B Cell Screening Technologies

Different single B cell technologies provide distinct advantages depending on project goals, antigen complexity, and downstream applications.

Platform	Best For	Key Advantages
FACS Single B Cell Sorting Platform	Rapid enrichment of antigen-specific B cells	High-throughput sorting, flexible marker selection, compatible with memory B cells
Beacon Single B Cell Platform	Functional antibody screening	Microfluidics-based real-time analysis of secretion, binding, and cellular activity
Antigen-Specific B Cell Screening	Rare antibody discovery	Isolation of low-frequency antigen-reactive B cells
Single Cell Antibody Sequencing	Recombinant antibody generation	Preservation of native VH/VL pairing for downstream expression

FACS-based systems primarily rely on fluorescence-labeled antigens and surface markers for cell isolation, while Beacon platforms provide additional functional screening capabilities at the single-cell level.

Supported Sample Types

Our single B cell workflows support multiple starting materials depending on project design and sample availability.

Sample quality, cell viability, and antigen labeling strategy can significantly influence screening performance and are evaluated during project planning.

Applications & Use Cases

Single B cell screening platforms are commonly used for:

• Rapid monoclonal antibody discovery
• Therapeutic antibody lead generation
• Neutralizing antibody screening
• Recombinant antibody development
• VHH/nanobody discovery
• Antibody repertoire analysis

Application-specific validation is not automatically included for all projects. Validation workflows can be customized based on downstream research requirements.

Overview of the Workflow

Phase	Service	Description	Deliverables	Timeline
Phase 1	Sample Preparation & Antigen Labeling	Preparation of immune cells and antigen-specific labeling strategy	Prepared cell samples, labeling confirmation	~1 week
Phase 2	Single B Cell Isolation	Isolation of antigen-specific B cells using FACS or Beacon systems	Single B cell populations	1–2 weeks
Phase 3	Antibody Gene Amplification & Sequencing	Recovery and sequencing of VH/VL regions	Antibody sequence data	~1 week
Phase 4	Recombinant Antibody Expression	Recombinant production of selected antibody candidates	Purified recombinant antibodies	2–3 weeks
Phase 5	Quality Control & Optional Validation	Basic QC and optional functional characterization	QC report, binding data (if requested)	~1 week

Typical total timeline: ~5–8 weeks
Timelines may vary depending on sample quality, screening complexity, and expression requirements.

Downstream Antibody Development Options

Following single B cell discovery, additional engineering and optimization services are available:

Integrated downstream workflows can help accelerate progression from antibody discovery to functional characterization.

Quality & Validation

We implement quality control and analytical strategies appropriate for single-cell antibody discovery workflows.

Standard Quality Control
Cell viability assessment, Sequence verification, Recombinant antibody purity analysis

Functional Validation (performed upon request)
ELISA binding analysis, Neutralization or blocking assays, Flow cytometry validation, Comparative binding studies

Optional Characterization
Affinity measurement (SPR or BLI), Epitope binning, Cross-reactivity analysis

Validation scope is determined during project planning and may vary depending on assay complexity and research objectives.

Why Researchers Choose Biocrest Science

• Integrated single-cell screening capabilities – FACS and Beacon platforms available within one workflow
• Rapid antibody discovery timelines – Efficient progression from B cell isolation to recombinant antibody generation
• Flexible species and sample support – Compatible with multiple immune cell sources and antibody formats
• Scientist-led workflow optimization – Customized screening strategies based on antigen and project goals
• Expandable downstream development services – Seamless transition into expression, engineering, and humanization workflows

Because antibody discovery outcomes depend on sample quality, antigen design, and immune response, screening performance can vary between projects. Our team works to optimize each stage while maintaining realistic expectations regarding hit rates and downstream validation.

Start Your Project

Whether you are screening for therapeutic antibody leads, recombinant antibodies, or nanobody candidates, our team can help design a single B cell workflow aligned with your research goals.

• Submit antigen information or sample details for evaluation
• Consult with our scientists on FACS vs Beacon platform selection
• Request a quote based on screening scale and downstream requirements